NKGen Biotech Administers First Dose of Troculeucel to Alzheimer’s Patient

SANTA ANA, Calif., July 10, 2025 — NKGen Biotech, Inc. (OTC: NKGN), a clinical-stage biotechnology company based in Santa Ana, United States, has announced the administration of the first dose of troculeucel, an expanded autologous natural killer (NK) cell therapy, to a patient with mild-stage Alzheimer’s disease. This treatment was administered under a single compassionate use, Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA).

The patient, who had been experiencing continued cognitive decline despite ongoing treatment with lecanemab, an amyloid-targeting therapy, was selected for this exploratory treatment. The initiative is being conducted in collaboration with Anita Fletcher, M.D., a board-certified neurologist with specialized training in neuroimmunology, who also serves as Director of Neuroscience Clinical Research at AdventHealth Neuroscience Institute in Orlando, Florida.

While NKGen’s ongoing double-blind randomized Phase 2a trial is focused on moderate-stage Alzheimer’s disease (NCT06189963), this single-IND marks the company’s first potential expansion into the treatment of mild Alzheimer’s, particularly for patients who fail to respond to existing first-line therapies. This initiative highlights NKGen’s dedication to advancing innovative therapies for neurodegenerative and oncological diseases.

Company Overview

NKGen Biotech, Inc. specializes in developing and commercializing autologous, allogeneic, and CAR-NK natural killer cell therapies. The company is listed on the OTC Bulletin Board and trades in USD. As of July 8, 2025, the close price of NKGen Biotech Inc. was $0.301, with a 52-week high of $1.37 on July 17, 2024, and a 52-week low of $0.098 on April 8, 2025. The company has a market capitalization of $16,170,000 and a price-to-earnings ratio of -0.145158.

This development represents a significant step for NKGen Biotech as it explores new therapeutic avenues for Alzheimer’s disease, aiming to provide solutions for patients who have not benefited from current treatments.